We are live on ! Find out more

Amgen

AMGN

Market cap $222B

410.24 USD

+17.08

4.34%

At close Updated Sep 22, 4:00 PM EDT

Pre-market

After hours

409.75

-0.49

0.12%

1 day

4.34%

5 days

8.81%

1 month

-7.57%

3 months

19.01%

6 months

17.29%

Year to date

25.21%

1 year

43.44%

5 years

92.02%

10 years

133.6%

About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees: 31,500

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 48.8%

Neutral 27.3%

Negative 24%

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data

Amgen Inc. (NASDAQ:AMGN) has reported encouraging topline outcomes from its Phase 3 OASIZ 301 study. The trial assessed the efficacy of dazodalibep in adult patients suffering from Sjögren's disease accompanied by moderate-to-severe systemic disease activity.

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data

Investors Business Daily

Amgen Boasts Success In Sjogren's; Shares Charge Ahead

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.

Amgen Boasts Success In Sjogren's; Shares Charge Ahead

Amgen's autoimmune drug succeeds in late-stage trial

Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing ‌glands met the main goal of reducing disease activity in a late-stage trial.

Amgen's autoimmune drug succeeds in late-stage trial

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

24/7 Wall Street

Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?

Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations.

Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?

Zacks Investment Research

Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

In the most recent trading session, Amgen (AMGN) closed at $385.65, indicating a +1.55% shift from the previous trading day.

Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

The Motley Fool

Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022

Amgen has proven that it can manage market downturns fairly well. The company is also an excellent dividend stock.

Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022

Zacks Investment Research

September Syndrome in Full Swing: 3 Picks to Safeguard Your Portfolio

September's market jitters highlight defensive stocks, ADM, AMGN and SUN, with low betas, high yields, raising 2026 guidance and improving earnings estimates.

September Syndrome in Full Swing: 3 Picks to Safeguard Your Portfolio

Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities

Amgen NASDAQ: AMGN outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns.

Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities

Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

See News Rankings

Price charts implemented using Lightweight Charts™